当前位置: X-MOL 学术Lancet HIV › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension
The Lancet HIV ( IF 12.8 ) Pub Date : 2024-10-09 , DOI: 10.1016/s2352-3018(24)00235-2
Prof Moses R Kamya PhD, Laura B Balzer PhD, James Ayieko PhD, Jane Kabami MPH, Elijah Kakande MD, Gabriel Chamie MD, Nicole Sutter MPH, Helen Sunday MBChB, Janice Litunya MBChB, Joshua Schwab MS, John Schrom, Melanie Bacon RN, Catherine A Koss MD, Alex R Rinehart PhD, Prof Maya Petersen PhD, Prof Diane V Havlir MD, SEARCH Consortium

HIV infections are ongoing globally despite efficacious biomedical prevention options. We sought to determine whether an HIV prevention package providing choice of daily pills or long-acting injectable cabotegravir and opportunities to change prevention options could increase biomedical prevention coverage and reduce new HIV infections.

中文翻译:


在乌干达和肯尼亚农村地区使用 cabotegravir 长效注射剂动态选择 HIV 预防:随机试验扩展



尽管有有效的生物医学预防选择,但 HIV 感染在全球范围内仍在进行。我们试图确定提供每日药丸或长效注射卡博特韦选择以及改变预防选择的机会的 HIV 预防包是否可以增加生物医学预防覆盖率并减少新的 HIV 感染。
更新日期:2024-10-09
down
wechat
bug